Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer
Triple-Negative Breast Carcinoma
Explore 428 assets in Triple-Negative Breast Carcinoma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Jules Bordet Institute
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03616886CT.gov Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC | — | Active Not Recruiting | — | — | — |
NCT03742102CT.gov A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer (this asset) | Jules Bordet Institute | P1/2 | CC · 41 |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
| Adriamycin | Yuan Yuan | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Pembrolizumab | M.D. Anderson Cancer Center | P3 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 63 |
| Pancreatic Adenocarcinoma | — | P2 | B · 59 |
| Colorectal Cancer | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-5-nucleotidase-human-monoclonal-medi9447-heavy-chain-disulfide-with-human-monoclonal-medi9447-lambda-chain-dimer-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →